Glucagon-like peptide-1 gene therapy - Sanofi Genzyme

Drug Profile

Glucagon-like peptide-1 gene therapy - Sanofi Genzyme

Alternative Names: Type 2 diabetes gene therapy

Latest Information Update: 27 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 27 Dec 2016 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 04 May 2006 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 26 Jun 2003 Data presented at the 63rd Scientific Sessions of the American Diabetes Association (ADA-2003)have been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top